R. Merkx

Carbonic Anhydrase IX: Current and Emerging Therapies

E. Oosterwijk, P. Mulders, R. Merkx, 2021, Progress in Drug Research.

Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma

E. Oosterwijk, P. Mulders, A. Kluge, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model

E. Oosterwijk, P. Mulders, F. Bruchertseifer, 2022, Pharmaceuticals.

Effectiveness of Heated Sterile Water vs ResoClear® for Prevention of Laparoscopic Lens Fogging in a Randomized Comparative Trial.

J. Langenhuijsen, P. Poyck, M. Warlé, 2018, Journal of endourology.

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

C. V. van Herpen, M. Gotthardt, S. Heskamp, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).

J. Bernhard, B. Shuch, A. Pantuck, 2023, Journal of Clinical Oncology.

Therapeutic efficacy and tolerability of [225Ac]Ac-DOTA-hG250 targeted alpha therapy in a clear cell renal cell carcinoma mice model

E. Oosterwijk, P. Mulders, F. Bruchertseifer, 2020 .

225Ac-labeled Girentuximab for Targeted Alpha Therapy of CAIX-expressing Renal Cell Cancer Xenografts

E. Oosterwijk, P. Mulders, F. Bruchertseifer, 2019, Journal of Medical Imaging and Radiation Sciences.

British Nuclear Medicine Society Autumn Meeting 2023.

A. Pantuck, D. Gramberg, L. Livieratos, 2023, Nuclear medicine communications.